uniQure(US:QURE)2025-02-27 13:03Financial Performance - Revenue for the year ended December 31, 2024, was $27.1 million, an increase of 71.4% compared to $15.8 million in 2023[6] - Total revenues for 2024 reached $27,119,000, a significant increase from $15,843,000 in 2023, representing a growth of 71.5%[22] - License revenues increased to $10,133,000 in 2024, compared to $2,758,000 in 2023, marking a growth of 267.5%[22] - Collaboration revenues rose to $10,872,000 in 2024, up from $2,250,000 in 2023, reflecting a growth of 384.4%[22] - The net loss for the year ended December 31, 2024, was $239.6 million, a decrease from a net loss of $308.5 million in 2023[14] - Net loss for 2024 was $239,556,000, an improvement from a net loss of $308,478,000 in 2023, indicating a reduction of 22.4%[22] - Basic and diluted net loss per ordinary share improved to $4.92 in 2024 from $6.47 in 2023[22] Expenses - Research and development expenses decreased to $143.8 million in 2024 from $214.9 million in 2023, reflecting a reduction of $71.1 million[9] - Selling, general and administrative expenses were $52.7 million for the year ended December 31, 2024, down from $74.6 million in 2023, a decrease of $21.9 million[10] - Total operating expenses decreased to $214,766,000 in 2024 from $303,083,000 in 2023, a reduction of 29.1%[22] Cash and Assets - Cash and cash equivalents as of December 31, 2024, were approximately $367.5 million, with proforma cash including net proceeds from a recent offering totaling around $448 million[5] - Total current assets decreased to $390,289,000 in 2024 from $651,853,000 in 2023, a decline of 40.1%[20] - Cash and cash equivalents decreased to $158,930,000 in 2024 from $241,360,000 in 2023, a decline of 34.2%[20] Liabilities and Equity - Total liabilities decreased to $563,288,000 in 2024 from $624,019,000 in 2023, a reduction of 9.7%[20] - Total shareholders' equity turned negative at $(6,752,000) in 2024, down from $207,670,000 in 2023[20] Clinical Developments - The company completed enrollment of all 12 patients in the third cohort of the AMT-130 study in February 2025, with an initial safety update expected in Q2 2025[4] - The FDA granted RMAT designation for AMT-130 in May 2024, indicating its potential to address unmet medical needs for Huntington's disease[4] - The company expects to fund operations into the second half of 2027 based on its current cash position and planned U.S. launch of AMT-130[5] - The company initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epilepsy, with protocol changes to expand inclusion criteria[2] - The company anticipates presenting data from ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission in Q3 2025[4]